Cell and Gene Therapy Manufacturing: Building the Future of Medicine One Cell at a Time

Cell and gene therapy (CGT) manufacturing represents one of the most transformative shifts in modern medicine, redefining how diseases are treated at their root cause rather than merely managing symptoms. Unlike conventional pharmaceuticals, these therapies involve the modification or utilization of living cells or genetic material to treat, prevent, or potentially cure diseases such as cancer, rare genetic disorders, and chronic conditions. According to insights from DelveInsight, the global cell and gene therapy manufacturing market was valued at USD 4.7 billion in 2025 and is projected to reach USD 9.8 billion by 2034, growing at a CAGR of 9.50%, reflecting the increasing demand for advanced therapeutics.

The rapid growth of CGT is driven by rising disease prevalence, advancements in biotechnology, and increased investments in research and manufacturing infrastructure. CGT manufacturing is thus not just a technical process; it is the backbone enabling these groundbreaking therapies to reach patients safely and effectively.

What Makes CGT Manufacturing Unique?

CGT manufacturing is fundamentally different from traditional drug manufacturing due to its reliance on living cells and complex biological systems. Unlike small-molecule drugs that are chemically synthesized, CGT products are highly personalized, often derived from the patient’s own cells or donor cells. This inherent variability introduces significant challenges in scalability, reproducibility, and quality control.

One of the defining characteristics of CGT manufacturing is its patient-specific nature. For example, in therapies like CAR-T cell therapy, a patient’s immune cells are extracted, genetically modified, expanded, and reinfused. This individualized approach requires highly controlled environments, advanced bioprocessing techniques, and strict traceability systems to ensure each product is matched to the correct patient. Another unique aspect is the complexity of biological materials. Cells are sensitive to environmental conditions such as temperature, pH, and oxygen levels, making their handling and processing far more intricate than traditional drugs. Additionally, CGT manufacturing must comply with stringent regulatory standards to ensure safety, efficacy, and consistency.

The lack of standardization further differentiates CGT manufacturing. Each therapy may require a customized process, specialized equipment, and unique quality control measures. This complexity is compounded by the need for rapid turnaround times, particularly for autologous therapies where delays can impact patient outcomes. Finally, the integration of advanced technologies such as automation, digital monitoring, and artificial intelligence is essential to manage variability and improve efficiency. These features collectively make CGT manufacturing a highly specialized and evolving field within the biopharmaceutical industry.

Key Steps in the Manufacturing Process

The manufacturing of cell and gene therapies involves a multi-step process that combines biological science with advanced engineering. Each step is critical to ensuring the final product is safe, effective, and of high quality. The process typically begins with cell collection, where patient or donor cells are obtained through procedures such as leukapheresis. These cells are then transported to a manufacturing facility under controlled conditions to preserve their viability.

The next step is cell isolation and selection, where specific cell types are separated from the collected sample. This is followed by genetic modification, a key step in gene therapy and certain cell therapies, where genes are introduced, removed, or altered using viral vectors or other gene-editing technologies.  Once modified, the cells undergo cell expansion, where they are cultured and multiplied to achieve the required therapeutic dose. This step requires precise control of environmental conditions and nutrients to ensure optimal cell growth and functionality.

After expansion, the cells are subjected to harvesting and purification processes to remove impurities and ensure product consistency. This is followed by formulation and fill-finish, where the final product is prepared for administration, often involving cryopreservation to maintain cell viability during storage and transport. Quality control is integrated throughout the process, with rigorous testing conducted at multiple stages to verify identity, potency, purity, and safety. Regulatory compliance is critical, as these therapies must meet strict guidelines before being approved for clinical use. Overall, the CGT manufacturing process is highly intricate, requiring coordination across multiple steps and disciplines to deliver a viable therapeutic product.

Technology Driving the Next Wave

Technological innovation is at the heart of advancements in CGT manufacturing. As the demand for these therapies grows, new technologies are being developed to improve efficiency, scalability, and cost-effectiveness. One of the most significant advancements is the adoption of automation and closed-system manufacturing. These systems minimize human intervention, reducing the risk of contamination and improving reproducibility. Automation also enables higher throughput, addressing one of the key challenges in scaling CGT production.

Another critical technology is viral vector production, which plays a central role in gene therapy by delivering genetic material into target cells. Advances in vector design and manufacturing have improved efficiency and reduced costs, making gene therapies more accessible. Gene-editing technologies, such as CRISPR-Cas9, are revolutionizing the field by enabling precise modifications to genetic material. These tools are expanding the range of treatable diseases and enhancing the effectiveness of therapies.

Digital technologies, including artificial intelligence and data analytics, are also transforming CGT manufacturing. These tools enable real-time monitoring, predictive maintenance, and process optimization, helping manufacturers manage variability and improve outcomes. Additionally, innovations in bioreactor design and cell culture systems are enhancing the scalability of cell expansion processes. These technologies allow for more efficient production while maintaining the quality and functionality of cells. Collectively, these advancements are driving the next wave of CGT manufacturing, enabling the transition from experimental therapies to commercially viable treatments.

The CDMO Ecosystem

The complexity and cost associated with CGT manufacturing have led to the rise of Contract Development and Manufacturing Organizations (CDMOs). These organizations provide specialized services that support the development and production of cell and gene therapies, allowing biotech companies to focus on research and innovation.

CDMOs play a critical role in addressing capacity constraints and technical challenges in CGT manufacturing. They offer end-to-end solutions, including process development, clinical manufacturing, and commercial-scale production. This is particularly important given the rapid expansion of the CGT pipeline and the increasing number of therapies entering clinical trials. The CDMO ecosystem is characterized by strategic partnerships and collaborations between pharmaceutical companies, biotech firms, and academic institutions. These collaborations enable knowledge sharing, resource optimization, and faster development timelines.

In recent years, there has been a significant increase in investments in CDMO infrastructure, including state-of-the-art manufacturing facilities and advanced technologies. This expansion is essential to meet the growing demand for CGT products and to support the commercialization of therapies. Moreover, CDMOs are playing a key role in standardizing processes and improving scalability, helping to overcome some of the inherent challenges in CGT manufacturing. Their expertise and capabilities are critical to the success of the CGT industry.

Future Outlook of CGT Manufacturing

The future of CGT manufacturing is poised for significant growth and innovation, driven by advancements in technology, increasing investment, and a growing pipeline of therapies. As the market continues to expand, the focus will shift toward improving scalability, reducing costs, and enhancing accessibility. One of the key trends shaping the future is the transition from autologous to allogeneic therapies, which have the potential to be produced at scale and distributed more widely. This shift could significantly reduce costs and increase patient access to these therapies.

Another important development is the integration of digital and automation technologies, which will enable more efficient and reliable manufacturing processes. These advancements will be critical in addressing the challenges of variability and scalability. The expansion of global manufacturing infrastructure is also expected to play a significant role in the future of CGT. Emerging markets, including countries in the Asia-Pacific, are investing in biotechnology capabilities to support local production and reduce dependency on imports.

Regulatory frameworks are evolving to keep pace with the rapid advancements in CGT, with agencies such as the FDA introducing expedited approval pathways to accelerate the development and commercialization of therapies. Despite these advancements, challenges remain, including high costs, complex supply chains, and stringent regulatory requirements. However, ongoing innovation and collaboration across the industry are expected to address these challenges and drive continued growth.

In conclusion, cell and gene therapy manufacturing is at the forefront of a new era in medicine, offering the potential to cure diseases that were once considered untreatable. By building the future of medicine one cell at a time, CGT manufacturing is transforming healthcare and paving the way for more personalized, effective, and life-changing treatments.